Please assess the completion status of the following clinical trial:

Trial Title: PPI and Clopidogrel Response

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteers aged between 18 and 75 years~Exclusion Criteria:~1. Known allergies to clopidogrel or omeprazole.~2. Blood dyscrasia or bleeding diathesis.~3. Recent antiplatelet treatment (\< 30 days) with a glycoprotein IIb/IIIa antagonist, thienopyridine (ticlopidine, clopidogrel), cilostazol or dipyridamole.~4. Treatment with other medications that may interfere with the CYP system (ketoconazole, itraconazole, diltiazem, erythromycin, clarithromycin, fluvoxamine, fluoxetine, nefazodone, or sertraline).~5. Platelet count \<100x106/microL.~6. Diabetes mellitus~7. History of coronary artery disease, gastrointestinal bleed, gastroesophageal reflux disease (GERD), cerebrovascular event or any active malignancy.~8. Active bleeding or hemodynamic instability.~9. Serum creatinine \>2mg/dL.~10. Baseline ALT \>2.5 times the upper limit of normal.~11. Pregnant females.~12. Patients taking omeprazole or any H2 antagonist or proton pump inhibitors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Omeprazole (Type: ACTIVE_COMPARATOR): prospective, open-label, two-sequence, three-period, randomized crossover study
- Pantoprazole (Type: ACTIVE_COMPARATOR): prospective, open-label, two-sequence, three-period, randomized crossover study

Based on this trial design, predict the completion outcome and termination type (if applicable).